Clinical Trial

A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study employs a non-randomized, open-label design to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of DC50292A tablets in patients with MTAP-deficient advanced or metastatic solid tumors. The study consists of two parts: dose escalation and dose expansion.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-08.
Trial Details
NCT Number NCT07071090
Lead Sponsor Heronova Pharmaceuticals
Conditions Solid Tumor Malignancies
Enrollment 32 participants
Start Date 2025-06-30
Primary Completion 2028-01-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-23